Holen Sie sich die Stockscreener-App
174.04
0.03%
-0.05
Insmed Inc Aktie (INSM) Neueste Nachrichten
Bronstein, Gewirtz & Grossman, LLC Is Investigating Insmed Incorporated (INSM) And Encourages Investors to Connect - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed ... - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed IncorporatedINSM - FinancialContent
INSM Investors Have Opportunity to Join Insmed Incorporated Fraud Investigation with the Schall Law Firm - Business Wire
Insmed's chief medical officer sells $2.97 million in stock - MSN
Insmed Incorporated (INSM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
INSM Quantitative Stock Analysis - Nasdaq
Rice Hall James & Associates LLC Sells 7,103 Shares of Insmed, Inc. $INSM - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Insmed Incorporated (INSM) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
A Closer Look at Insmed's Options Market DynamicsInsmed (NASDAQ:INSM) - Benzinga
The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar - sharewise.com
NASDAQ adding Alnylam, Ferrovial, Insmed, Monolithic Power at open on 12/22 - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Insmed Incorporated (INSM) Investors to Inquire about Securities Investigation - ACCESS Newswire
Insmed (FRA:IM8N) EV-to-OCF : -39.13 (As of Dec. 25, 2025) - GuruFocus
4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow - Finviz
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Insmed Incorporated (INSM) And Encourages Investors to Reach Out - ACCESS Newswire
Insmed sinks after brensocatib fails trial for sinus condition - MSN
Insmed Earnings Notes - Trefis
Insmed price target lowered to $230 from $240 at HC Wainwright - MSN
Insmed stock plunges nearly 20% after hours as sinus drug fails mid-stage trial and shows no benefit - MSN
Pharmaceutical Stocks To ConsiderDecember 21st - MarketBeat
Why Insmed Incorporated stock is considered a top pickMarket Sentiment Extremes & Free Professional Investment Consultations - Bollywood Helpline
Medical Stocks Worth WatchingDecember 18th - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Insmed Incorporated (INSM) And Encourages Stockholders to Reach Out - ACCESS Newswire
Insmed, Inc. (NASDAQ:INSM) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Insmed (INSM) Stock After Hours Today (Dec. 22, 2025): Closing Price, Nasdaq-100 Effect, Fresh Forecasts, and What to Watch Before Tuesday’s Open - ts2.tech
Insmed (INSM) Stock News Today: Nasdaq‑100 Addition, Brensocatib Setback, and Updated Analyst Forecasts (Dec. 22, 2025) - ts2.tech
Insmed Incorporated(NasdaqGS: INSM) added to NASDAQ-100 Index - marketscreener.com
How analysts rate Insmed Incorporated stock today2025 Support & Resistance & Momentum Based Trading Ideas - Улправда
What is HC Wainwright's Forecast for Insmed FY2025 Earnings? - MarketBeat
Insmed (INSM) Stock: What to Know Before the Market Opens on Dec. 22, 2025 - ts2.tech
Insmed Incorporated (NASDAQ: INSM) Stock Week Ahead: Nasdaq-100 Addition Meets Brensocatib Setback—News, Forecasts, and What to Watch (Dec. 22–26, 2025) - ts2.tech
Nike, Insmed, And Arm Are Among Top 10 Large Cap Losers Last Week (Dec. 15-Dec. 19): Are the Others in Your Portfolio?ARM Holdings (NASDAQ:ARM), BitMine Immersion (AMEX:BMNR), Insmed (NASDAQ:INSM), Lennar (NYSE:LEN) - Benzinga
INSM stock plummets on sinus study failure, adds new pipeline asset - MSN
Voya Investment Management LLC Sells 187,840 Shares of Insmed, Inc. $INSM - MarketBeat
Insmed (BIT:1INSM) Price Target Increased by 16.99% to 218.23 - Nasdaq
The 'worst-case scenario' — why Insmed just reversed after a 181% six-month sprint - MSN
Insmed (INSM) Stock News and Forecasts on Dec. 20, 2025: Brinsupri Trial Miss, Truist Upgrade, and Updated Price Targets - ts2.tech
Insmed Inc. buy Truist Financial Co. - sharewise.com
Truist Financial Upgrades Insmed (NASDAQ:INSM) to "Strong-Buy" - MarketBeat
Assenagon Asset Management S.A. Grows Position in Insmed, Inc. $INSM - MarketBeat
Brinsupri setback slices Insmed market cap — Clinical Report - biocentury.com
Will Insmed Incorporated (IM8N) stock announce a stock splitPortfolio Performance Summary & Accurate Intraday Trading Signals - ulpravda.ru
Weekly Buzz: CYTK Scores First FDA Approval, INSM Ends Rhinosinusitis Study, XOMA Acquires GBIO - RTTNews
What risks investors should watch in Insmed Incorporated stockWeekly Risk Summary & Stock Portfolio Risk Control - ulpravda.ru
Insider Selling: Insmed (NASDAQ:INSM) CEO Sells 10,699 Shares of Stock - MarketBeat
Insmed Insider Sold Shares Worth $1,786,457, According to a Recent SEC Filing - marketscreener.com
INSMED Chair and CEO William Lewis Sells 10,699 Shares - TradingView — Track All Markets
Insmed Stock (INSM) Rebounds on Dec. 19, 2025 After BiRCh Trial Miss: Latest News, Analyst Forecasts, and What Comes Next - ts2.tech
Insmed (MIL:1INSM) EV-to-FCF : -35.92 (As of Dec. 19, 2025) - GuruFocus
Insmed (MIL:1INSM) EV-to-OCF : -36.87 (As of Dec. 19, 2025) - GuruFocus
Will Insmed Incorporated (IM8N) stock test record highs in 2025July 2025 Macro Moves & Scalable Portfolio Growth Methods - DonanımHaber
Insmed Delivers ‘Rare Disappointment’ as Brinsupri Flops in Mid-Stage Rhinosinusitis Study - BioSpace
Goldman Sachs reiterates Buy rating on Insmed stock despite trial setback - Investing.com
FY2028 Earnings Estimate for Insmed Issued By HC Wainwright - MarketBeat
Is Insmed Incorporated stock a good choice for value investorsJuly 2025 Fed Impact & AI Enhanced Trading Signals - DonanımHaber
How Insmed Incorporated (IM8N) stock correlates with oil marketsBond Market & Real-Time Volume Analysis Alerts - Улправда
Truist Securities assumes coverage on Insmed stock with Buy rating By Investing.com - Investing.com Canada
Truist Securities assumes coverage on Insmed stock with Buy rating - Investing.com
How Insmed Incorporated stock performs in high volatility markets2025 Retail Activity & Technical Buy Zone Confirmation - DonanımHaber
0.30%
0.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):